Preliminary Results

AI SummaryClose X

CelLBxHealth plc reported preliminary results for the year ended 31 December 2025, showing total revenue of £1.4 million, down from £2.9 million in 2024, with product and services revenue at £1.1 million and biopharma services at £0.3 million. The company experienced an operating loss of £19.2 million, an increase from £15.1 million in the prior year, and a loss after tax of £19.5 million. Despite these figures, gross profit margins remained stable at 62%, and a £8.2 million fundraise was completed in December 2025, leaving the company with £7.3 million in cash and cash equivalents. Significant restructuring efforts have reduced annualised operating cash costs to approximately £6.7 million, and the company anticipates FY 2026 revenues to be at least £2.1 million, representing at least 50% growth.

Disclaimer*

UK 100

Latest directors dealings